Monica Ortiz-Rivera, MD
Endocrinology, Diabetes & Metabolism · San Juan, PRNPI 1063962058
Payments from drug & device makers
What this record shows
This record is dominated by grants: $140,625 of the $147,655 with a category attached, or 95.2%. Eli Lilly Export S.A. Puerto Rico Branch accounts for 63.7% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2021 at $94,456 and has fallen 98.7% since, to $1,272 in 2025. Among endocrinology, diabetes & metabolism clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 196 payments — averaging $753.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly Export S.A. Puerto Rico Branch$94K
- Eli Lilly$47K
- Medtronic$959
- Boehringer Ingelheim$825
- Dexcom, Inc.$687
- Novo Nordisk$665
- plus $4K from 18 others
What the payments were for
- Grants$140,62595%
- Travel & lodging$7851%
- Food & beverage$6,1514%
- Education$950%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly Export S.A. Puerto Rico Branch | 10 | $94,011 |
| Eli Lilly | 1 | $46,875 |
| Medtronic | 11 | $959 |
| Boehringer Ingelheim | 27 | $825 |
| Dexcom, Inc. | 20 | $687 |
| Novo Nordisk | 30 | $665 |
| Amgen | 9 | $652 |
| Sanofi-aventis U.S. LLC | 16 | $532 |
| Lilly USA, LLC | 5 | $463 |
| Bayer | 5 | $433 |
| AstraZeneca | 12 | $306 |
| PBG Puerto Rico LLC | 10 | $213 |
| Abbott | 9 | $185 |
| Johnson & Johnson | 6 | $132 |
| Kyowa Kirin, Inc. | 1 | $126 |
| Bayer Puerto Rico Inc. | 6 | $117 |
| BETA Bionics, Inc. | 1 | $116 |
| Novartis | 4 | $102 |
| Merck | 4 | $72 |
| Scpharmaceuticals Inc. | 3 | $59 |
| Vifor Pharma, Inc. | 2 | $44 |
| AbbVie | 2 | $36 |
| Radius Health, Inc. | 1 | $25 |
| Boston Scientific | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NIM Vital$716
- iLet Bionic Pancreas$347
- ZEPBOUND$320
- JARDIANCE$250
- Repatha$250
- DEXCOM G7 GSS (161)$246
- Kerendia$232
- TOUJEO$130
- SOLIQUA 100/33$130
- Ozempic$125
- EVENITY$122
- DEXCOM STELO GLUCOSE BIOSENSOR$121
- MOUNJARO$119
- iLet Insulin Infusion Kit Inset$116
- iLet Insulin Infusion Kit Contact Detach$116
- FARXIGA$109
How this compares
$147,655 in reported general payments places this provider in the 95th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
See all endocrinology, diabetes & metabolism providers in Puerto Rico →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 99 | $102,715 |
| MounjaroTirzepatide | 71 | $76,165 |
| JardianceEmpagliflozin | 71 | $66,148 |
| Jentadueto XrLinagliptin/Metformin Hcl | 99 | $56,537 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 81 | $53,227 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 67 | $52,180 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 73 | $51,663 |
| GlyxambiEmpagliflozin/Linagliptin | 47 | $34,862 |
| TradjentaLinagliptin | 54 | $34,275 |
| SynthroidLevothyroxine Sodium | 303 | $23,493 |
| FarxigaDapagliflozin Propanediol | 25 | $23,296 |
| TrulicityDulaglutide | 21 | $20,752 |
| Xigduo XrDapaglifloz Propaned/Metformin | 16 | $18,067 |
| LantusInsulin Glargine,hum.Rec.Anlog | 103 | $11,079 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $10,793 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Jentadueto Xr, Synjardy Xr, Trijardy Xr, Glyxambi | $825 | $296,713425 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $463 | $105,943187 claims |
| Novo NordiskOzempic | $665 | $102,71599 claims |
| MerckJanumet Xr | $72 | $52,18067 claims |
| AbbVieSynthroid | $36 | $23,493303 claims |
| AstraZenecaFarxiga | $306 | $23,29625 claims |
| Sanofi-aventis U.S. LLCLantus, Soliqua 100-33 | $532 | $21,872115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
Other endocrinology, diabetes & metabolism in San Juan
- Manuel Alegre-HernandezSan Juan$156K
- Alex Gonzalez BossoloSan Juan$110K
- Michelle Mangual GarciaSan Juan$87K
- Meliza Martinez RodriguezSan Juan$80K
- Jorge de Jesus MirandaSan Juan$30K
- Zahira Lugo LopezSan Juan$29K
- Oscar Ruiz BermudezSan Juan$27K
- Margarita Ramirez-VickSan Juan$15K
- Yanira Marrero McFalineSan Juan$14K
- Alfredo Sanchez CruzSan Juan$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.